Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-09-15
2002-12-03
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S379000
Reexamination Certificate
active
06489350
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to methods of treating neuropathic pain with heteroarylmethanesulfonamides.
References
Ahmad, S. N. and Miljanich, G. P.,
Brain Research
453:247-256 (1988).
Bennett, G. J. and Xie, Y.-K.,
Pain
33:87-107 (1988).
Bennett, J. P. et al., in
NEUROTRANSMITRER RECEPTOR BINDING
, pp. 61-89; Raven press, New York, N.Y. (1983).
Ben-Sreti, M. M., et al.,
Eur. J. Pharmacol
. 90:385-391 (1983).
Contreras, E., et al.,
Eur. J. Pharmacol
. 148:463-466 (1988).
Dixon, W. J.,
Ann. Rev. Pharmacol. Toxicol
. 20:441-462 (1976).
Jadad, A. R., et al.,
Lancet
339:1367-1371 (1992).
Kenakin, T. P., in
PHARMACOLOGIC ANALYSIS OF DRUG
-
RECEPTOR INTERACTION
, Raven Press, New York, N.Y. (1987).
Kim, S. H. and Chung, J. M.,
Pain
50:355-363 (1992).
McCleskey, E. W., et al.,
Proc. Natl. Acad. Sci. USA
84:4327-31 (1987).
McGeer, P. L., et al., in
MOLECULAR NEUROBIOLOGY OF THE MAMMALIAN BRAIN
, Plenum Press, New York, N.Y. (1987).
Sher, E. et al.,
FASEB J
. 5:2677-2683 (1991).
Sher, E. and Clementi, F.,
Neuroscience
42301-42307 (1991).
Yaksh, T. L., and Rudy, T. A.,
Physiol. Behav
. 17:1031-1036 (1976).
Cesena R. M.; Calcutt N. A.,
Neurosci Lett
(IRELAND) 262(2):101-4 (1999)
Malmberg A. B. and Yaksh T. L.,
J. Pharmacol. Exp. Ther
. 263: 136-146 (1992).
BACKGROUND OF THE INVENTION
Chronic or intractable pain, as may occur in conditions such as bone degenerative diseases, AIDS, Reflex sympathetic dystrophy (RSD), and cancer, is a debilitating condition which is treated with a variety of analgesic agents, and often opioid compounds, such as morphine. This type of pain is classified as nociceptive and is experienced in response to potentially tissue-damaging thermal, mechanical or chemical energy impinging upon specialized nerve endings of A and C fibers. Thus pain is usually perceived in response to nociceptive signaling by the nervous system as a result of noxious stimuli.
A few examples of neuropathic pain syndromes without nociception, i.e., not in response to noxious external stimuli are: diabetic neuropathy; postparapalegia pain; postherpetic neuralgia; reflex sympathetic dystrophy; thalamic syndrome; nerve root avulsion pain; phantom limb pain; postthoracotomy pain; tic douloureux and arachnoiditis.
Neuropathic pain, then, is a particular type of pain that has a complex and variable etiology. It is frequently a chronic condition attributable to complete or partial transection of a nerve, trauma or injury to a nerve, nerve plexus or soft tissue, or other conditions, also including cancer, AIDS and idiopathic causes. Neuropathic pain is characterized by hyperalgesia (lowered pain threshold and enhanced pain perception) and/or by allodynia (pain from innocuous mechanical or thermal stimuli). The condition is progressive in nature. The hyperesthetic component of neuropathic pain does not respond to the same pharmaceutical interventions as do the more usual nociceptive forms of pain, and development of effective long-term treatment modalities has been problematic. Repeated C fiber stimulation results in increased spinal afferent processing which is probably related to the hyperalgesia and allodynia symptoms. Evidence points to a complex scenario in which continued C fiber stimulation leads to local spinal release of glutamate, which activates spinal N-methyl-D-aspartate receptors. This activation then leads to increased intracellular Ca and later to spinal formation of several intermediaries, including prostanoids and nitric oxide. Both intermediaries facilitate spinal processing of signals directly by increasing the release of spinal neurotransmitters, and lead to the facilitated state of hyper-responsive pain signaling that lacks true nociceptive stimulus.
Opioid compounds (opiates) such as morphine, while effective in producing analgesia for many types of nociceptive pain, are generally not effective for treating the progressive stages of neuropathic pain. Moreover, if somewhat effective, these compounds are known to induce tolerance in patients, so that increased doses are required to achieve a satisfactory analgesic effect. At high doses, these compounds produce side effects (such as respiratory depression) which can be life threatening. In addition, opioids can produce physical dependence in patients.
Calcium blocking agents, including a number of L-type calcium channel antagonists, were tested as adjunct therapy to morphine analgesia, and positive results were attributed to their direct effects on calcium availability, since calcium itself is known to attenuate the analgesic effects of certain opioid compounds (Ben-Sreti, et al., 1983). EGTA, a calcium chelating agent, is effective in increasing the analgesic effects of opioids. However, results from tests of calcium antagonists as adjunct therapy to other opioids have been contradictory; some L-type calcium channel antagonists have been shown to increase the analgesic effects of opioids, while others of these compounds have been shown to decrease opioid effects (Contreras, et al., 1988).
U.S. Pat. No. 5,364,842 and 5,587,454 describe the effectiveness of N-type calcium channel blocking omega-conopeptide compositions in certain animal models of pain, including neuropathic pain. However, these compounds, being peptides, are not easily administered orally, but rather may be administered into the cerebrospinal fluid or other areas of the spinal column. By contrast, zonisamide is a T- and L-type calcium channel blocker and tests in animals (see Examples) have shown oral activity.
The anticonvulsant agent gabapentin exhibits anti-hyperalgesic properties in animal models of neuropathic pain. Diabetic rats display increased nocifensive behavior (i.e. avoidance behavior of stimuli) during the formalin test of persistent chemical irritation to the paw, suggesting the presence of abnormal pain processing mechanisms. In a study based on formalin-evoked behavior in diabetic rats, they were shown to have increased flinching during the normally quiescent phase of the 5.0% formalin test. Gabapentin (50 mg/kg i.p. 30 min pre-test) suppressed flinching during phases 1 and 2 of the formalin test in both control and diabetic rats. The findings were interpreted as showing efficacy of gabapentin against abnormal sensory processing in diabetic rats and the possible benefit for treating painful diabetic neuropathy. Since gabapenitin is an approved drug for use in humans in epilepsy, it has also be used in treatment of neuropathic pain, but the rather high dosages required to obtain a therapeutic effect make it undesireable for treatment of certain segments (e.g. the elderly) of the patient population.
Gabapentin (1-(aminomethyl)cyclohexaneacetic acid) is structurally related to the neurotransmitter GABA (gamma-aminobutyric acid) but it does not interact with GABA receptors, nor is it converted metabolically into GABA or a GABA agonist, nor is it an inhibitor of GABA uptake or degradation. Gabapentin was tested in radioligand binding assays at concentrations up to 100 &mgr;M and did not exhibit affinity for a number of other common receptor sites, including benzodiazepine, glutamate, N-methyl-D-aspartate (NMDA), quisqualate, kainate, strychnine-insensitive or strychnine-sensitive glycine, alpha
1
, alpha
2
, or beta adrenergic, adenosine A
1
or A
2
, cholinergic, muscarinic or nicotinic, dopamine D
1
or D
2
, histamine H
1
, serotonin S
1
or S
2
, opiate mu, delta or kappa, voltage-sensitive calcium channel sites labeled with nitrendipine or diltiazem, or at voltage-sensitive sodium channel sites with batrachotoxinin A 20-alpha-benzoate (excerpt from Physicians Desk Reference (1999 PDR Supplement B) Edition monograph for Neurontin Capsules). In vitro studies with radiolabeled gabapentin have revealed a gabapentin binding site in areas of rat brain including neocortex and hippocampus. although the identity and function of this binding site remain to be elucidated.
The heteroaryl methanesulfonamides of the invention are described in U.S. Pat. No. 4,172,896, which is hereby incorporated herein by referen
Elan Pharmaceuticals Inc.
Hoch J. Mark
Spivack Phyllis G.
LandOfFree
Methods for treating neuropathic pain using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating neuropathic pain using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating neuropathic pain using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2940232